Free Fatty Acid Receptor 1 (G Protein Coupled Receptor 40 or GPR40 or FFAR1) - Pipeline Review, H2 2016

Free Fatty Acid Receptor 1 (G Protein Coupled Receptor 40 or GPR40 or FFAR1) - Pipeline Review, H2 2016


  • Products Id :- GMDHC0516TDB
  • |
  • Pages: 52
  • |
  • |
  • |
  Request for Sample Report
  Request A Quote

Executive Summary

Free Fatty Acid Receptor 1 (G Protein Coupled Receptor 40 or GPR40 or FFAR1) - Pipeline Review, H2 2016

Summary

Global Markets Direct's, 'Free Fatty Acid Receptor 1 (G Protein Coupled Receptor 40 or GPR40 or FFAR1) - Pipeline Review, H2 2016', provides in depth analysis on Free Fatty Acid Receptor 1 (G Protein Coupled Receptor 40 or GPR40 or FFAR1) targeted pipeline therapeutics.

The report provides comprehensive information on the Free Fatty Acid Receptor 1 (G Protein Coupled Receptor 40 or GPR40 or FFAR1), targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in Free Fatty Acid Receptor 1 (G Protein Coupled Receptor 40 or GPR40 or FFAR1) targeted therapeutics development and features dormant and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note:

*Certain sections in the report may be removed or altered based on the availability and relevance of data.

*Updated report will be delivered in 48 hours of order confirmation.

Scope

- The report provides a snapshot of the global therapeutic landscape for Free Fatty Acid Receptor 1 (G Protein Coupled Receptor 40 or GPR40 or FFAR1)

- The report reviews Free Fatty Acid Receptor 1 (G Protein Coupled Receptor 40 or GPR40 or FFAR1) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources

- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

- The report reviews key players involved in Free Fatty Acid Receptor 1 (G Protein Coupled Receptor 40 or GPR40 or FFAR1) targeted therapeutics and enlists all their major and minor projects

- The report assesses Free Fatty Acid Receptor 1 (G Protein Coupled Receptor 40 or GPR40 or FFAR1) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type

- The report summarizes all the dormant and discontinued pipeline projects

- The report reviews latest news and deals related to Free Fatty Acid Receptor 1 (G Protein Coupled Receptor 40 or GPR40 or FFAR1) targeted therapeutics

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

- Identify and understand the targeted therapy areas and indications for Free Fatty Acid Receptor 1 (G Protein Coupled Receptor 40 or GPR40 or FFAR1)

- Identify the use of drugs for target identification and drug repurposing

- Identify potential new clients or partners in the target demographic

- Develop strategic initiatives by understanding the focus areas of leading companies

- Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics

- Devise corrective measures for pipeline projects by understanding Free Fatty Acid Receptor 1 (G Protein Coupled Receptor 40 or GPR40 or FFAR1) development landscape

- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope



Read More



Contact Us:
Ken Research
Ankur Gupta, Head Marketing & Communications

+91-9015378249

Table of Contents

Table of Contents 2

List of Tables 5

List of Figures 5

Introduction 6

Global Markets Direct Report Coverage 6

Free Fatty Acid Receptor 1 (G Protein Coupled Receptor 40 or GPR40 or FFAR1) Overview 7

Therapeutics Development 8

Free Fatty Acid Receptor 1 (G Protein Coupled Receptor 40 or GPR40 or FFAR1) - Products under Development by Stage of Development 8

Free Fatty Acid Receptor 1 (G Protein Coupled Receptor 40 or GPR40 or FFAR1) - Products under Development by Therapy Area 9

Free Fatty Acid Receptor 1 (G Protein Coupled Receptor 40 or GPR40 or FFAR1) - Products under Development by Indication 10

Free Fatty Acid Receptor 1 (G Protein Coupled Receptor 40 or GPR40 or FFAR1) - Pipeline Products Glance 11

Late Stage Products 11

Early Stage Products 12

Free Fatty Acid Receptor 1 (G Protein Coupled Receptor 40 or GPR40 or FFAR1) - Products under Development by Companies 13

Free Fatty Acid Receptor 1 (G Protein Coupled Receptor 40 or GPR40 or FFAR1) - Products under Development by Universities/Institutes 15

Free Fatty Acid Receptor 1 (G Protein Coupled Receptor 40 or GPR40 or FFAR1) - Therapeutics Assessment 17

Assessment by Monotherapy/Combination Products 17

Assessment by Mechanism of Action 18

Assessment by Route of Administration 20

Assessment by Molecule Type 21

Free Fatty Acid Receptor 1 (G Protein Coupled Receptor 40 or GPR40 or FFAR1) - Companies Involved in Therapeutics Development 22

Advinus Therapeutics Ltd 22

Amgen Inc. 23

Astellas Pharma Inc. 24

Caldan Therapeutics Limited 25

Connexios Life Sciences Pvt. Ltd. 26

Daiichi Sankyo Company, Limited 27

Hyundai Pharmaceutical Co., Ltd. 28

Japan Tobacco Inc. 29

Jiangsu Hengrui Medicine Co., Ltd. 30

Merck & Co., Inc. 31

Free Fatty Acid Receptor 1 (G Protein Coupled Receptor 40 or GPR40 or FFAR1) - Drug Profiles 32

AM-1638 - Drug Profile 32

Product Description 32

Mechanism Of Action 32

R&D Progress 32

AM-3189 - Drug Profile 33

Product Description 33

Mechanism Of Action 33

R&D Progress 33

AM-6226 - Drug Profile 34

Product Description 34

Mechanism Of Action 34

R&D Progress 34

AS-2034178 - Drug Profile 35

Product Description 35

Mechanism Of Action 35

R&D Progress 35

AS-2575959 - Drug Profile 36

Product Description 36

Mechanism Of Action 36

R&D Progress 36

CNX-01167 - Drug Profile 37

Product Description 37

Mechanism Of Action 37

R&D Progress 37

DS-1558 - Drug Profile 38

Product Description 38

Mechanism Of Action 38

R&D Progress 38

HD-6277 - Drug Profile 39

Product Description 39

Mechanism Of Action 39

R&D Progress 39

JTT-851 - Drug Profile 40

Product Description 40

Mechanism Of Action 40

R&D Progress 40

MK-8666 - Drug Profile 41

Product Description 41

Mechanism Of Action 41

R&D Progress 41

Small Molecule to Agonize GPR40 and GPR120 Receptors for Type 2 Diabetes - Drug Profile 42

Product Description 42

Mechanism Of Action 42

R&D Progress 42

Small Molecule to Agonize GPR40 for Type 2 Diabetes - Drug Profile 43

Product Description 43

Mechanism Of Action 43

R&D Progress 43

Small Molecule to Antagonize GPR40 for Obesity - Drug Profile 44

Product Description 44

Mechanism Of Action 44

R&D Progress 44

Small Molecules to Agonize GPR40 for Diabetes - Drug Profile 45

Product Description 45

Mechanism Of Action 45

R&D Progress 45

TUG-770 - Drug Profile 46

Product Description 46

Mechanism Of Action 46

R&D Progress 46

Free Fatty Acid Receptor 1 (G Protein Coupled Receptor 40 or GPR40 or FFAR1) - Dormant Projects 47

Free Fatty Acid Receptor 1 (G Protein Coupled Receptor 40 or GPR40 or FFAR1) - Discontinued Products 48

Free Fatty Acid Receptor 1 (G Protein Coupled Receptor 40 or GPR40 or FFAR1) - Featured News & Press Releases 49

Apr 10, 2012: Connexios in discussions to partner early-stage GPR40 diabetes drug, CRO will be chosen in US/EU -CEO 49

Jun 27, 2011: Connexios Life Science Presents Preclinical Data On CNX-011-67 At American Diabetes Association Meeting 49

Appendix 51

Methodology 51

Coverage 51

Secondary Research 51

Primary Research 51

Expert Panel Validation 51

Contact Us 51

Disclaimer 52

List of Figures

Number of Products under Development for, H2 2016 8

Number of Products under Development by Indication, H2 2016 10

Comparative Analysis by Early Stage Products, H2 2016 12

Assessment by Monotherapy/Combination Products, H2 2016 17

Number of Products by Mechanism of Actions, H2 2016 18

Number of Products by Stage and Mechanism of Actions, H2 2016 19

Number of Products by Stage and Routes of Administration, H2 2016 20

Number of Products by Stage and Molecule Type, H2 2016 21

List of Tables

Number of Products under Development for, H2 2016 8

Number of Products under Development by Therapy Area, H2 2016 9

Number of Products under Development by Indication, H2 2016 10

Comparative Analysis by Late Stage Development, H2 2016 11

Comparative Analysis by Early Stage Products, H2 2016 12

Number of Products under Development by Companies, H2 2016 13

Products under Development by Companies, H2 2016 14

Number of Products under Investigation by Universities/Institutes, H2 2016 15

Products under Investigation by Universities/Institutes, H2 2016 16

Assessment by Monotherapy/Combination Products, H2 2016 17

Number of Products by Stage and Mechanism of Action, H2 2016 19

Number of Products by Stage and Route of Administration, H2 2016 20

Number of Products by Stage and Molecule Type, H2 2016 21

Pipeline by Advinus Therapeutics Ltd, H2 2016 22

Pipeline by Amgen Inc., H2 2016 23

Pipeline by Astellas Pharma Inc., H2 2016 24

Pipeline by Caldan Therapeutics Limited, H2 2016 25

Pipeline by Connexios Life Sciences Pvt. Ltd., H2 2016 26

Pipeline by Daiichi Sankyo Company, Limited, H2 2016 27

Pipeline by Hyundai Pharmaceutical Co., Ltd., H2 2016 28

Pipeline by Japan Tobacco Inc., H2 2016 29

Pipeline by Jiangsu Hengrui Medicine Co., Ltd., H2 2016 30

Pipeline by Merck & Co., Inc., H2 2016 31

Dormant Projects, H2 2016 47

Discontinued Products, H2 2016 48

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to query [@] kenresearch.com
 

Advinus Therapeutics Ltd

Amgen Inc.

Astellas Pharma Inc.

Caldan Therapeutics Limited

Connexios Life Sciences Pvt. Ltd.

Daiichi Sankyo Company, Limited

Hyundai Pharmaceutical Co., Ltd.

Japan Tobacco Inc.

Jiangsu Hengrui Medicine Co., Ltd.

Merck & Co., Inc.

Free Fatty Acid Receptor 1 (G Protein Coupled Receptor 40 or GPR40 or FFAR1) Therapeutic Products under Development, Key Players in Free Fatty Acid Receptor 1 (G Protein Coupled Receptor 40 or GPR40 or FFAR1) Therapeutics, Free Fatty Acid Receptor 1 (G Protein Coupled Receptor 40 or GPR40 or FFAR1) Pipeline Overview, Free Fatty Acid Receptor 1 (G Protein Coupled Receptor 40 or GPR40 or FFAR1) Pipeline, Free Fatty Acid Receptor 1 (G Protein Coupled Receptor 40 or GPR40 or FFAR1) Pipeline Assessment

select a license

Single User License
USD 3500 INR 224910
Site License
USD 7000 INR 449820
Corporate User License
USD 10500 INR 674730

NEWSLETTER BY CATEGORY




Testimonials

The report sent to us was on the point, and its information was quite extensive, well structured, and well researched. More importantly what we valued was your response time and professionalism. As a leading global consulting firm, our clients expect high quality deliverables in short periods of time, so a reliable research partner is essential. For the price that you have charged the quality of your services were exceptional. We look forward to continue our relationship with your team on future engagements....

This is with regards to your report on India PVC pipes and fitting market outlook industry outlook to 2019. This is a very well written report and accept my compliments on the same.... ...

I am pleased to see the very useful and productive information in the report..Very well structured great presentation reflect professionalism in your research studies....

While we still are studying and analysing your reports about Vietnam & Thailand, we would like to convey to your research team that they have done a very good job in compiling so much of information together. We hope to see more of such well researched reports. All the best & keep it up. ...

We would like to appreciate Ken Research for their great efforts and wonderful support in providing the Market Intelligence Report for ITPC. The information, statistics and research are well understandable and very clear to the point. We are happy with Ken research for their good client service, on-time delivery of the report and as said the report itself. Thank you Ken research for bringing the valuable output for us. We would be looking forward to have more research with you in the near future. Wish you a success in your business!...



Related Products in vertical
Ken Research Pvt. Ltd. Unit 14, Tower B3, Spaze I Tech Business Park, Sohna Road, sector 49
     Gurgaon, Haryana - 122001, India

download

Company Brochure

Engage with Us

query [@] kenresearch.com